Alteration in spectral properties on ligand binding reveals flexibility in monoamine oxidase

Medical Science Monitor

Volumn 11, Issue 9, 2005, Pages

  Ramsay, Rona R ^a   Jones, Tadeusz Z E ^a   Hynson, Robert M G ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Antidepressant; Circular dichroism; Flavin; Inhibitor; Monoamine oxidase A; Oxazolidinone; Oxidative stress; Pirlindole

Indexed keywords

ALANINE; AMINE OXIDASE (FLAVIN CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CYSTEINE; QUERCETIN; SEMIQUINONE; THIOL DERIVATIVE;

ALLOSTERISM; CATALYSIS; CIRCULAR DICHROISM; CONFORMATION; CRYSTAL STRUCTURE; ENZYME ACTIVITY; LIGAND BINDING; OXIDATION KINETICS; OXIDATIVE STRESS; REVIEW; STRUCTURE ANALYSIS; SURFACE PROPERTY;

ALLOSTERIC REGULATION; ANIMALS; CATALYTIC DOMAIN; CYSTEINE; HUMANS; KINETICS; LIGANDS; MODELS, MOLECULAR; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; OXIDATION-REDUCTION; PROTEIN CONFORMATION;

EID: 24944574725     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Singer TP, Ramsay RR: Mechanism of the Neurotoxicity of Mptp - an Update. FEBS Lett, 1990; 274: 1-8
2. Wouters J: Structural aspects of monoamine oxidase and its reversible inhibition. Curr Med Chem, 1998; 5: 137-62
3. Kalgutkar AS, Dalvie DK, Castagnoli N, Taylor TJ: Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. Chem Res Toxicol, 2001; 14: 1139-62
4. Veselovsky AV, Ivanov AS, Medvedev AE: Computer Modelling and Visualization of Active Site of Monoamine Oxidases, 2004; 25: 37-46
5. Ramsay RR, Gravestock MB: Monoamine oxidases: to inhibit or not to inhibit. Mini-Rev Med Chem, 2003; 3: 129-36
6. Binda C, Newton-Vinson P, Hubalek F et al: Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat Struct Biol, 2002; 9: 22-26
7. Binda C, Li M, Hubalek F, Restelli N et al: Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures, 2003; 100: 750-55
8. Ma JC, Yoshimura M, Yamashita E et al: Structure of rat monoamine oxidase A and its specific recognitions for substrates and inhibitors. J Mol Biol, 2004; 338: 103-14
9. Ramsay RR: Kinetic Mechanism of Monoamine Oxidase-A. Biochemistry, 1991; 30: 4624-29
10. Hynson RMG, Kelly SM, Price NC, Ramsay RR: Conformational changes in monoamine oxidase A in response to ligand binding or reduction. Biochim Biophys Acta-Gen Subj, 2004; 1672: 60-66
11. Ramsay RR, Hunter DJB: Inhibitors alter the spectrum and redox properties of monoamine oxidase A. BBA-Proteins Proteomics, 2002; 1601: 178-84
12. Hynson RMG, Wouters J, Ramsay RR: Monoamine oxidase A inhibitory potency and flavin perturbation are influenced by different aspects of pirlindole inhibitor structure. Biochem Pharmacol, 2003; 65: 1867-74
13. Moureau F, Wouters J, Depas M et al: A Reversible Monoamine-Oxidase Inhibitor Toloxatone - Comparison of Its Physicochemical Properties with Those of Other Inhibitors Including Brofarimine, Harmine, R40519 and Moclobemide. Eur J Med Chem, 1995; 30: 823-38
14. Sablin SO, Ramsay RR: Monoamine oxidase contains a redox-active disulfide. J Biol Chem, 1998; 273: 14074-76
15. Rigby SEJ, Hynson RMG, Ramsay RR et al: A stable tyrosyl radical in monoamine oxidase A. J Biol Chem. 2004; M410596200
16. Parini A, Moudanos CG, Pizzinat N, Lanier SM: The elusive family of imidazoline binding sites. Trends Pharmacol Sci, 1996; 17: 13-16
17. Raddatz R, Savic SL, Bakthavachalam V et al: Imidazoline-binding domains on monoamine oxidase B and subpopulations of enzyme. J Pharmacol Exp Ther, 2000; 292: 1135-45
18. Remaury A, Raddatz R, Ordener C et al: Analysis of the pharmacological and molecular heterogeneity of I-2-imidazoline-binding proteins using monoamine oxidase- deficient mouse models. Mol Pharmacol, 2000; 58: 1085-90
19. Paterson LM, Tyacke RJ, Nutt DJ, Hudson AL: Relationship between imidazoline(2) sites and monoamine oxidase. In: Agmatine and Imidazolines: Their Novel Receptors and Enzymes, 2003; Vol. 1009: 353-56
20. Weyler W, Salach JI: Purification and Properties of Mitochondrial Monoamine-Oxidase Type-a from Human-Placenta. J Biol Chem, 1985; 260: 3199-207
21. Hubalek F, Edmondson DE: Thiol reactivities as probes of MAO A and MAO B structure and function. In: Flavins and Flavoproteins 2002 (Eds. Chapman SK, Perham RN and Scrutton NS), Rudolf Weber, Berlin, 2002; 217-22
22. Wu HF, Chen K, Shih JC: Site-Directed Mutagenesis of Monoamine Oxidase-a and Oxidase-B - Role of Cysteines. Mol Pharmacol, 1993; 43: 888-93
23. Mitchell DJ, Silverman RB, Singer TP et al: Nuclear magnetic resonance and mass spectroscopic evidence for the flavin-1-phenylcyclopropylamine inactivator adduct of monoamine oxidase. Biochemistry, 2000; 39: 52
24. Vintem A-PB, Ramsay RR, Silverman RB: Subtle differences between MAO A and its cysteine 374 mutant during mechanism-based inactivation by cyclopropylamines. In: Flavins and Flavoproteins 2002 (Ed. SK Chapman RNPaNSS), Rudolph Weber, Berlin, 2002; 911-15
25. Iglesias-Osma MC, Garcia-Barrado MJ, Visentin V et al: Benzylamine exhibits insulin-like effects on glucose disposal, glucose transport, and fat cell lipolysis in rabbits and diabetic mice. J Pharmacol Exp Ther, 2004; 309: 1020-28
26. Ben-Shachar D, Zuk R, Gazawi H, Ljubuncic P: Dopamine toxicity involves mitochondrial complex I inhibition: implications to dopamine-related neuropsychiatric disorders. Biochem Pharmacol, 2004; 67: 1965-74